A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)Todd M. Cooper, Patrick A. Brown, Amina Ahmed et al.|Pediatric Blood & Cancer|2017Cited by 73
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLLia Gore, Bodour Salhia, Timothy J. Triche et al.|Clinical Epigenetics|2017Cited by 45
<p>Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma</p>Lucy Swift, Aru Narendran|OncoTargets and Therapy|2019Cited by 12
Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10Son Tran, Aru Narendran|Cancers|2024Cited by 0